Zura Bio price target lowered to $19 from $20 at Oppenheimer

Oppenheimer analyst Justin Kim lowered the firm’s price target on Zura Bio (ZURA) to $19 from $20 and keeps an Outperform rating on the shares after the company released year-end financial and operational results for 2024. Year-ending cash of $176.5M is anticipated to support operations through 2027, however this does not include funds for major clinical work beyond systemic sclerosis and HS trials, the firm notes.